150 related articles for article (PubMed ID: 36571471)
1. Oral capsules of tetra-hydro-cannabinol (THC), cannabidiol (CBD) and their combination in peripheral neuropathic pain treatment.
Zubcevic K; Petersen M; Bach FW; Heinesen A; Enggaard TP; Almdal TP; Holbech JV; Vase L; Jensen TS; Hansen CS; Finnerup NB; Sindrup SH
Eur J Pain; 2023 Apr; 27(4):492-506. PubMed ID: 36571471
[TBL] [Abstract][Full Text] [Related]
2. A double-blind, randomized, placebo-controlled, parallel group study of THC/CBD spray in peripheral neuropathic pain treatment.
Serpell M; Ratcliffe S; Hovorka J; Schofield M; Taylor L; Lauder H; Ehler E
Eur J Pain; 2014 Aug; 18(7):999-1012. PubMed ID: 24420962
[TBL] [Abstract][Full Text] [Related]
3. A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis.
Langford RM; Mares J; Novotna A; Vachova M; Novakova I; Notcutt W; Ratcliffe S
J Neurol; 2013 Apr; 260(4):984-97. PubMed ID: 23180178
[TBL] [Abstract][Full Text] [Related]
4. Cannabis-based medicines for chronic neuropathic pain in adults.
Mücke M; Phillips T; Radbruch L; Petzke F; Häuser W
Cochrane Database Syst Rev; 2018 Mar; 3(3):CD012182. PubMed ID: 29513392
[TBL] [Abstract][Full Text] [Related]
5. Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial.
Rog DJ; Nurmikko TJ; Young CA
Clin Ther; 2007 Sep; 29(9):2068-79. PubMed ID: 18035205
[TBL] [Abstract][Full Text] [Related]
6. Cannabis constituent synergy in a mouse neuropathic pain model.
Casey SL; Atwal N; Vaughan CW
Pain; 2017 Dec; 158(12):2452-2460. PubMed ID: 28885457
[TBL] [Abstract][Full Text] [Related]
7. Oral efficacy of Δ(9)-tetrahydrocannabinol and cannabidiol in a mouse neuropathic pain model.
Mitchell VA; Harley J; Casey SL; Vaughan AC; Winters BL; Vaughan CW
Neuropharmacology; 2021 May; 189():108529. PubMed ID: 33741405
[TBL] [Abstract][Full Text] [Related]
8. Single and combined effects of Δ
King KM; Myers AM; Soroka-Monzo AJ; Tuma RF; Tallarida RJ; Walker EA; Ward SJ
Br J Pharmacol; 2017 Sep; 174(17):2832-2841. PubMed ID: 28548225
[TBL] [Abstract][Full Text] [Related]
9. Sativex
Markovà J; Essner U; Akmaz B; Marinelli M; Trompke C; Lentschat A; Vila C
Int J Neurosci; 2019 Feb; 129(2):119-128. PubMed ID: 29792372
[TBL] [Abstract][Full Text] [Related]
10. Oral medicinal cannabinoids to relieve symptom burden in the palliative care of patients with advanced cancer: a double-blind, placebo-controlled, randomised clinical trial of efficacy and safety of 1:1 delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD).
Hardy J; Haywood A; Gogna G; Martin J; Yates P; Greer R; Good P
Trials; 2020 Jul; 21(1):611. PubMed ID: 32631447
[TBL] [Abstract][Full Text] [Related]
11. A multicentre, open-label, follow-on study to assess the long-term maintenance of effect, tolerance and safety of THC/CBD oromucosal spray in the management of neuropathic pain.
Hoggart B; Ratcliffe S; Ehler E; Simpson KH; Hovorka J; Lejčko J; Taylor L; Lauder H; Serpell M
J Neurol; 2015 Jan; 262(1):27-40. PubMed ID: 25270679
[TBL] [Abstract][Full Text] [Related]
12. The detection of THC, CBD and CBN in the oral fluid of Sativex® patients using two on-site screening tests and LC-MS/MS.
Molnar A; Fu S; Lewis J; Allsop DJ; Copeland J
Forensic Sci Int; 2014 May; 238():113-9. PubMed ID: 24699310
[TBL] [Abstract][Full Text] [Related]
13. Cannabis constituents reduce seizure behavior in chemically-induced and scn1a-mutant zebrafish.
Thornton C; Dickson KE; Carty DR; Ashpole NM; Willett KL
Epilepsy Behav; 2020 Sep; 110():107152. PubMed ID: 32585475
[TBL] [Abstract][Full Text] [Related]
14. Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain.
Johnson JR; Burnell-Nugent M; Lossignol D; Ganae-Motan ED; Potts R; Fallon MT
J Pain Symptom Manage; 2010 Feb; 39(2):167-79. PubMed ID: 19896326
[TBL] [Abstract][Full Text] [Related]
15. Intrathecal Actions of the Cannabis Constituents Δ(9)-Tetrahydrocannabinol and Cannabidiol in a Mouse Neuropathic Pain Model.
Casey SL; Mitchell VA; Sokolaj EE; Winters BL; Vaughan CW
Int J Mol Sci; 2022 Aug; 23(15):. PubMed ID: 35955774
[TBL] [Abstract][Full Text] [Related]
16. Analysis of cannabidiol (CBD) and THC in nonprescription consumer products: Implications for patients and practitioners.
Miller OS; Elder EJ; Jones KJ; Gidal BE
Epilepsy Behav; 2022 Feb; 127():108514. PubMed ID: 34998268
[TBL] [Abstract][Full Text] [Related]
17. An experimental randomized study on the analgesic effects of pharmaceutical-grade cannabis in chronic pain patients with fibromyalgia.
van de Donk T; Niesters M; Kowal MA; Olofsen E; Dahan A; van Velzen M
Pain; 2019 Apr; 160(4):860-869. PubMed ID: 30585986
[TBL] [Abstract][Full Text] [Related]
18. A randomised controlled cross-over double-blind pilot study protocol on THC:CBD oromucosal spray efficacy as an add-on therapy for post-stroke spasticity.
Marinelli L; Balestrino M; Mori L; Puce L; Rosa GM; Giorello L; Currà A; Fattapposta F; Serrati C; Gandolfo C; Abbruzzese G; Trompetto C
BMJ Open; 2017 Sep; 7(9):e016843. PubMed ID: 28882919
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
